Navigation Links
New drug shows promise against multiple sclerosis
Date:11/1/2011

a remarkable finding," said Stephen Hauser, MD, the Robert A. Fishman Distinguished Professor and Chair of the Department of Neurology at UCSF who was the senior author on the study. "This is extremely exciting, both in terms of the prospect of improved therapy for people with multiple sclerosis but also for the lessons that it teaches us about the fundamental cause of the disease."

"The prospect of an extremely effective therapy for multiple sclerosis that can be safely administered at six month intervals could represent a major step forward, if the safety profile and benefits are sustained over longer periods of use," he added.

At 24 weeks, serious adverse events were reported in 4 percent of patients in the placebo arm, 4 percent of those taking interferon, and 2 percent and 6 percent of patients taking 600 mg and 2000 mg of Ocrelizumab. One patient taking Ocrelizumab died, but the relationship with the study drug, if any, is as yet unclear.

Hauser said that the next step for the drug will be to see if the drug's effect and positive safety profile will be sustained over time. These questions will be addressed in two parallel Phase 3 trials, now enrolling a larger number of patients who will receive the drug regimens for a longer period of time. This trial is now underway at several hundred sites around the world. Hauser serves as lead investigator for these trials, which are sponsored by Roche, the company that owns Ocrelizumab.

What the Trial Suggests About Multiple Sclerosis

Besides the obvious question of whether the drug would work, also under scrutiny in the clinical trial was whether a drug like Ocrelizumab would work in the first place. Its mechanism of action is fundamentally different than other existing therapies for multiple sclerosis. All multiple sclerosis drugs work by targeting a person's immune system only they target fundamentally different parts.

In multiple sclerosis, a person's im
'/>"/>

Contact: Jason Socrates Bardi
jason.bardi@ucsf.edu
415-502-4608
University of California - San Francisco
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Preterm birth rate shows three year improvement in most states
2. Study shows no increased risk of breast cancer for non-carriers in families with BRCA gene mutation
3. Novel approach to treat proliferative vitreoretinopathy shows promise
4. New therapy shows promise for treating cardiovascular disease
5. More Evidence Shows Newer Forms of Pill Raise Clot Risk, FDA Says
6. New oncolytic virus shows improved effectiveness in preclinical testing
7. Clinical trial shows first evidence that anal cancer is preventable
8. Through-the-nipple breast cancer therapy shows promise in early tests
9. Compound found in common wart treatment shows promise as leukemia therapy
10. Study shows why underrepresented men should be included in binge eating research
11. HIV Medication Patch Shows Promise in Early Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... ... September 04, 2015 , ... San Francisco cosmetic dentist ... CEREC is a newer method for creating restorations through innovative imaging equipment and ... the need for multiple appointments, CEREC produces restorations with total precision for a ...
(Date:9/4/2015)... ... ... Many consumers are looking for a quick and convenient way to produce a hot remedy ... Cups provide a quick and simple way to brew a hot cup of cold remedy ... a result, they enhance comfort and health. The invention features a novel design that is ...
(Date:9/4/2015)... ... 04, 2015 , ... The conference program for the upcoming ... 9-10, 2015 at the Diplomat Resort & Spa has been announced and is ... at the top of their field and will be presenting sessions such as ...
(Date:9/4/2015)... ... September 04, 2015 , ... Lalonde Gordon ran a 44.64 ... up with victory in the men’s 400 meters final, with an impressive 44.89 seconds ... Championships in San Jose, Costa Rica in August 2015. The 44.64 time is a ...
(Date:9/4/2015)... ... 2015 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has written an ... Pope’s upcoming trip to the United States. , Yisrayl lays out what he says is ... and society is. Yisrayl also provides the meaning of his own name and describes what ...
Breaking Medicine News(10 mins):Health News:San Francisco Dentist, Dr. Ben Amini, is Now Offering CEREC Technology at CitiDent 2Health News:Redesigned Packaging for Powdered Medicinal Mix Invented by InventHelp® Client (CBA-2637) 2Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 3Health News:Yisrayl Hawkins Writes Open Letter to Pope Francis In Light of Approaching U.S. Visit 2
... Thirty-year Communications Veteran Tasked with Expanding Opportunities for ... Breast Cancer Organization, DALLAS, Dec. 12 ... communications professionals, today was named chief marketing,officer for ... largest grassroots,network of breast cancer survivors and activists., ...
... Technologies Inc.,(TSX: NDQ), a developer of real-time ... the operating room, today announced that it ... North American Medical Imaging Product of,the Year ... Novadaq,company executives were recognized during Frost & ...
... Cross volunteer,Krysta Leigh Meinzer is featured in "Cause ... college network, profiling standout student,activists on college campuses ... an episode of the show, which is broadcast ... Think.MTV.com., (Photo: http://www.newscom.com/cgi-bin/prnh/20071212/DC09732 ), ...
... educate that drugs such as morphine are more than just ... -- Many cancer patients endure unnecessary suffering when they resist ... the use of these drugs signifies imminent death, a new ... range of available opioids in order to successfully manage pain ...
... 2007) A new study confirms that chronic kidney ... events in diabetic patients with damage to the large ... drug pioglitazone may help to lower this risk, reports ... , "The data confirm that chronic kidney disease is ...
... Minn. -- When a vaccine to prevent shingles was ... Administration recommended the vaccine for people age 60 and ... the vaccines cost and the perception that shingles primarily ... some physicians undecided about whether healthy adults need the ...
Cached Medicine News:Health News:Susan G. Komen for the Cure Names Tim Doke Chief Marketing Officer 2Health News:Novadaq's SPY Imaging System named Product of the Year by Frost and Sullivan 2Health News:Novadaq's SPY Imaging System named Product of the Year by Frost and Sullivan 3Health News:Novadaq's SPY Imaging System named Product of the Year by Frost and Sullivan 4Health News:Red Cross Blood Donor and Volunteer Featured on mtvU's 'CAUSE EFFECT' 2Health News:Cancer Patients Hold Fast to Belief That Opioids Mean Death 2Health News:Pioglitazone lowers cardiovascular risk in diabetic patients with kidney disease 2Health News:Mayo Clinic article offers data about shingles virus 2
(Date:9/3/2015)... NEW YORK , Sept. 3, 2015 About ... in dryness of eyes due to deficient tear production ... This syndrome is of two types: aqueous tear deficient ... deficient dry eye, lacrimal glands do not produce enough ... eye. Meibomian glands secrete lipids to slow tear evaporation ...
(Date:9/3/2015)... TAMPA, Fla. , Sept. 3, 2015  WellCare ... that Drew Asher , senior vice president and ... Wells Fargo Securities 2015 Healthcare Conference on Wednesday, September ... The presentation will be webcast live. In addition, a ... conclusion of the live broadcast. Both the live broadcast ...
(Date:9/3/2015)... VIEJO, Calif. , Sept. 3, 2015 /PRNewswire/ ... global pharmaceutical company, and AqueSys, Inc. a private ... ocular implants that reduce intraocular pressure (IOP) associated ... into an agreement under which Allergan will acquire ... of the agreement, Allergan will acquire AqueSys for ...
Breaking Medicine Technology:Global Dry Eye Syndrome Market 2015-2019 2Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 2Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 3Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 4Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 5Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 6
... IsoRay, Inc. (AMEX: ISR ), a ... medical radioisotope applications for brain cancer, lung cancer, head ... Dwight Babcock, Chairman and Chief Executive Officer, will co-present ... TIME:  5:00 PM EST LINK:   ...
... Africa, Nov. 29, 2011   Leatt Corporation (OTC: ... a neck brace system designed to help prevent potentially ... sports, today announced the formation of an agreement with ... New Zealand. Whites Powersports has more than ...
Cached Medicine Technology:IsoRay, Inc. to Webcast, Live, at RetailInvestorConferences.com on December 1st 2Leatt Announces Distribution Agreement With Whites Powersports for New Zealand Market 2
... generation access device - XPOSE 4 - ... The XPOSE 4 Device is designed to ... surgery and to easily position and access ... both apical and non-apical placement on the ...
... system is an intuitive, all-in-one endoscopic ... minimize the scarring and risk of ... Incorporating an enhanced, ergonomic handle design ... obstructions, this new device is intended ...
... includes three major components: Blood pump, Cannulae, ... Driver. This system provides partial or total ... conventional therapy, is unable to maintain adequate ... support, blood flows from the natural heart ...
... TISSEEL VH Fibrin Sealant has been shown ... surgical repair. Containing uniform, reproducible concentrations of ... simulates the final stage of the coagulation ... clot that firmly adheres to connective tissue ...
Medicine Products: